Selected Quarterly Financial Information

12 Months Ended

Dec. 31, 2018

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Information (Unaudited)

SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

(in thousands, except per share data)



	First			Second		Third		Fourth
	Quarter			Quarter		Quarter		Quarter
REVENUE:
2018	$	61,948		$	68,496	$	64,598	$	67,799
2017		45,059		$	47,818	$	43,999		52,826	*
2016		43,016	**		47,083		45,252		45,029

GROSS MARGIN:
2018	$	39,228		$	45,851	$	42,714	$	45,191
2017		29,512		$	32,905	$	29,862		36,363	*
2016		27,621	**		30,301		29,782		31,195

NET (LOSS) INCOME:
2018	$	(3,855)		$	226	$	1,565	$	(776)
2017		2,223		$	3,163	$	1,325		(3,007)	*
2016		2,541	**		2,347		2,993		2,897

(LOSS) INCOME PER COMMON SHARE—DILUTED:
2018	$	(0.11)		$	0.01	$	0.04	$	(0.02)
2017		0.06		$	0.09	$	0.04		0.09	*
2016		0.08	**		0.07		0.09		0.09

*In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly-owned subsidiary of CryoLife.

**In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly-owned subsidiary of CryoLife. In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.